BD Statement on FTC Clearance of Bard Acquisition
Dec 22, 2017
FRANKLIN LAKES, N.J., Dec. 22, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology companyissued the following statement regarding today's clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD’s soft tissue core needle biopsy product line and C. R. Bard's Aspira® product line of tunneled home drainage catheters and accessories:
"FTC approval brings us one step closer to full regulatory clearance of the Bard acquisition," said Vincent A. Forlenza, chairman and CEO of BD. "We currently expect that the Bard acquisition will close in December, pending approval by the Ministry of Commerce of the People’s Republic of China (MOFCOM) and the satisfaction of customary closing conditions."
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com.
Back to News Releases
Forward looking statements
This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to the pending acquisition of Bard by BD that involves substantial risks and uncertainties, including, among other things, risks related to the satisfaction of the conditions to closing the acquisition in the anticipated timeframe or at all. These statements are based on the current expectations of BD management and these statements speak only as of the date of this document. BD undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.